CellSource Co

CellSource Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CellSource Co (4880.T) as of Oct 27, 2026 is 166.71 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 185.47 M JPY — a change of -10.12% (lower).

EBITDA

166.71 MJPY

YoY

-10.12%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CellSource Co is 2025 166.71 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CellSource Co was 2024 185.47 M JPY. It decreases by -10.12% lower compared to the previous year.

The CellSource Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
297.91 M JPY
Jan 1, 2019
333.68 M JPY
Jan 1, 2020
423.57 M JPY
Jan 1, 2021
1.01 B JPY
Jan 1, 2022
1.58 B JPY
Jan 1, 2023
1.29 B JPY
Jan 1, 2024
185.47 M JPY
Jan 1, 2025
166.71 M JPY
The CellSource Co EBITDA history
YEAREBITDAYoY
166.71 MJPY-10.12%
185.47 MJPY-85.60%
1.29 BJPY-18.71%
1.58 BJPY+57.57%
1.01 BJPY+137.37%
423.57 MJPY+26.94%
333.68 MJPY+12.01%
297.91 MJPY+86.97%
159.33 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CellSource Co is 166.71 M JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of CellSource Co changed from 185.47 M JPY to 166.71 M JPY, representing a -10.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) CellSource Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSource Co

All Key Metrics — CellSource Co